Login to Your Account

Transition Therapeutics, Novo Deal Worth Up To $56M-Plus

By Randall Osborne

Monday, November 10, 2003
Transition Therapeutics Inc.'s Islet Neogenesis Therapy in Phase I for diabetes bagged the firm a deal potentially worth more than $56 million with Novo Nordisk A/S. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription